Gabapentin Tablet, Film Coated
Product Images NDC 72789-127

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72789-127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets (49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 01)

A formula showing the calculation of creatinine clearance (CLCr) based on age, weight, serum creatinine level, and sex factors, highlighting an adjustment for female patients multiplied by 0.85.*

FDA Label Image

Gabapentin Tablets (49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 02)

Chemical structure diagram of Gabapentin, showing its cyclohexane ring attached to an amino methyl group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

Gabapentin Tablets (49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 03)

A line graph depicting mean pain scores over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain score trend compared to placebo, which remains relatively stable.*

FDA Label Image

Gabapentin Tablets (49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 04)

Line graph showing mean pain scores over 7 weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis measures mean pain score from 0 to 10. Both gabapentin groups show a decrease in mean pain scores over time compared to placebo.*

FDA Label Image

Gabapentin Tablets (49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 05)

A bar chart comparing percentages for placebo (PBO) and Gabapentin (GBP) treatments in two studies. Study 1 shows PBO at 12% and GBP 3600 mg at 29%. Study 2 displays PBO at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin Tablets (49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 06)

A scatter plot chart showing the percentage difference versus daily dose (mg) for Gabapentin across three different studies labeled a, b, and c. The x-axis represents daily dose levels 600, 900, 1200, and 1800 mg, while the y-axis shows the difference percentage ranging from 2% to 22%. Data points for each study are marked with different square symbols and corresponding letters a, b, and c.*

FDA Label Image

72789127 Label (72789127)

Label for Gabapentin USP 600 mg film-coated tablets, containing 90 tablets per bottle. The product is manufactured and packaged by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label includes the NDC 72789-127-90 and lot number I20E68 with expiration date 11/2021. Safety warnings and dosage instructions are also printed on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.